Compositions and Methods for Treating Anemia (Vadadustat)

Assignee: Akebia Therapeutics, Inc. (and/or its licensors)
Patent Number: US 11,844,756 B2
Filing Date: (Derived from family; issued in prior years and active through 2025)
Title: Compositions and Methods for Treating Anemia
Status in 2025: Active/Enforced patent protecting vadadustat‑based therapies

What This Patent Covers

This U.S. patent protects:

Pharmaceutical compositions involving vadadustat (AKB‑6548) — a hypoxia‑inducible factor (HIF) prolyl hydroxylase inhibitor.
Methods of treating anemia, particularly anemia due to chronic kidney disease, by administering vadadustat to patients to stimulate endogenous erythropoietin (EPO) production and improve red blood cell production.
Claims generally cover the compound, its pharmaceutical formulations, dosing regimens, and therapeutic uses that modulate the HIF pathway to treat anemia associated with CKD.

Vadadustat acts by inhibiting hypoxia‑inducible factor prolyl hydroxylases, which stabilizes HIF‑alpha and promotes EPO synthesis — providing an oral alternative to injectable erythropoiesis‑stimulating agents (ESAs) for CKD anemia.

Why This Patent Is Important

Core Commercial Product: Vafseo® (vadadustat) was approved and commercially launched in the U.S. in January 2025 for the treatment of anemia due to chronic kidney disease in adult dialysis patients, generating significant revenue growth for Akebia.
Market Exclusivity: The patent provides critical protection for vadadustat‑based therapies, helping Akebia maintain exclusivity against generic competition and underpinning pricing leverage in the anemia treatment market.
Large Market Opportunity: Anemia due to CKD remains a multi‑billion‑dollar global market (hundreds of thousands of patients in dialysis and potentially larger if label expansion occurs), making this patent a linchpin of Akebia’s commercial strategy.
Lifecycle Strategy: With patent protections tied to vadadustat, Akebia can pursue label expansion (e.g., non‑dialysis CKD) and secure additional regulatory and reimbursement pathways that could broaden commercial value beyond initial launch.

Context on Patent Activity: While Akebia has multiple patents and applications covering formulations, methods of treatment, and manufacturing relating to its core compounds (including vadadustat and earlier assets like Auryxia®), the vadadustat composition and methods patent remains the most commercially crucial IP because it protects the product that is newly marketed and driving current and future revenues.

BioTech IP Review